Publications by authors named "M Jose Calasanz"

Claim this Profile
Q
Quizartinib for Newly Diagnosed -Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.
Pau Montesinos, Rebeca Rodríguez-Veiga, Juan Miguel Bergua, Jesús Lorenzo Algarra Algarra, Carmen Botella, Maria José Calasanz

J Clin Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Quizartinib for Newly Diagnosed -Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.
Pau Montesinos, Rebeca Rodríguez-Veiga, Juan Miguel Bergua, Jesús Lorenzo Algarra Algarra, Carmen Botella, Maria José Calasanz

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories.
Margarida Coucelo, Claudia Sargas, Rosa Ayala, María J Larráyoz, María Carmen Chillón, María J Calasanz

Leuk Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SOX4 in chronic lymphocytic leukaemia: the forgotten transcription factor.
Ricardo García-Muñoz, Jone Alberdi-Ballina, Giovanna Farfan-Quiroga, Eloy F Robles, María José Larráyoz, María José Calasanz

Blood Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From Sanger to Oxford Nanopore MinION Technology: The Impact of Third-Generation Sequencing on Genetic Hematological Diagnosis.
María José Larráyoz, Pablo Luri-Martin, Amagoia Mañu, Oihane Churruca, Natalia Gordillo, María José Calasanz

Cancers (Basel)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis